Journal of Nuclear Cardiology

, Volume 20, Issue 1, pp 120–127 | Cite as

Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis

  • Michael SoussanEmail author
  • Pierre-Yves Brillet
  • Hilario Nunes
  • Gabriel Pop
  • Matthieu-John Ouvrier
  • Nicolas Naggara
  • Dominique Valeyre
  • Pierre Weinmann
Original Article



We hypothesized that a high-fat and low-carbohydrate (HFLC) diet before FDG-PET/CT could identify patients with active cardiac sarcoidosis (CS).


Fifty-eight sarcoidosis patients with a suspicion of CS consumed a HFLC diet before FDG-PET/CT. Clinical, electrical, and other imaging investigations were compared to PET results.


Using Japanese Ministry of Health and Welfare (JMHW) criteria as a gold standard, 21% (12/58) of patients had a CS. Sensitivity and specificity of PET (visual analysis) were 83% (10/12) and 78% (36/46), respectively, with a very good interobserver agreement (k = 0.86). 70% (7/10) of the patients with a positive PET and negative JMHW criteria exhibited abnormalities suggestive of CS either on MR (n = 3) or SPECT (n = 4). Comparison with the presence of delayed enhancement on magnetic resonance imaging helped to classify patients with active (PET positive) or non-active CS (PET negative). In addition, when MR and PET were both negative, none of the patients met the JMHW criteria. PET response under treatment was concordant with clinical evolution in 11/13 patients.


FDG-PET/CT after HFLC diet is a sensitive tool for the diagnosis of active CS. Combined use of PET and MR is promising for the detection and characterization of CS lesions.


Myocarditis PET/CT imaging fluorodeoxyglucose (FDG) 


Conflict of interest

The authors declare no conflict of interest.


  1. 1.
    Aubart F, Diebold B, Dhote R, Weinmann P, Valeyre D. Cardiac sarcoidosis. Rev Mal Respir 2003;20:S45-9.PubMedGoogle Scholar
  2. 2.
    Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J 2009;157:9-21.PubMedCrossRefGoogle Scholar
  3. 3.
    Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord 2007;27:89-102 (in Japanese).Google Scholar
  4. 4.
    Ohira H, Tsujino I, Yoshinaga K. (18)F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2011;38:1773-83.PubMedCrossRefGoogle Scholar
  5. 5.
    Pandya C, Brunken RC, Tchou P, Schoenhagen P, Culver DA. Detecting cardiac involvement in sarcoidosis: A call for prospective studies of newer imaging techniques. Eur Respir J 2007;29:418-22.PubMedCrossRefGoogle Scholar
  6. 6.
    Kaneta T, Hakamatsuka T, Takanami K, Yamada T, Takase K, Sato A, et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med 2006;20:203-8.PubMedCrossRefGoogle Scholar
  7. 7.
    Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-43.PubMedCrossRefGoogle Scholar
  8. 8.
    Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-10.PubMedCrossRefGoogle Scholar
  9. 9.
    Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-41.PubMedCrossRefGoogle Scholar
  10. 10.
    Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98.PubMedGoogle Scholar
  11. 11.
    Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med 2003;44:1030-6.PubMedGoogle Scholar
  12. 12.
    Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol 2008;190:W151-6.PubMedCrossRefGoogle Scholar
  13. 13.
    Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol 2011;18:926-36.PubMedCrossRefGoogle Scholar
  14. 14.
    Frayn KN. The glucose-fatty acid cycle: A physiological perspective. Biochem Soc Trans 2003;31:1115-9.PubMedCrossRefGoogle Scholar
  15. 15.
    Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-9.PubMedCrossRefGoogle Scholar
  16. 16.
    Buckley O, Doyle L, Padera R, Lakdawala N, Dorbala S, Di Carli M, et al. Cardiomyopathy of uncertain etiology: Complementary role of multimodality imaging with cardiac MRI and 18FDG PET. J Nucl Cardiol 2010;17:328-32.PubMedCrossRefGoogle Scholar
  17. 17.
    Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153-65.PubMedCrossRefGoogle Scholar
  18. 18.
    Cummings KW, Bhalla S, Javidan-Nejad C, Bierhals AJ, Gutierrez FR, Woodard PK. A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR imaging. Radiographics 2009;29:89-103.PubMedCrossRefGoogle Scholar
  19. 19.
    Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42.PubMedCrossRefGoogle Scholar
  20. 20.
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.PubMedCrossRefGoogle Scholar
  21. 21.
    Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991.Google Scholar
  22. 22.
    Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010;3:1219-28.PubMedCrossRefGoogle Scholar
  23. 23.
    Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.PubMedCrossRefGoogle Scholar
  24. 24.
    Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-11.PubMedCrossRefGoogle Scholar
  25. 25.
    Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;45:1683-90.PubMedCrossRefGoogle Scholar
  26. 26.
    Vignaux O. Cardiac sarcoidosis: Spectrum of MRI features. AJR Am J Roentgenol 2005;184:249-54.PubMedCrossRefGoogle Scholar
  27. 27.
    Isiguzo M, Brunken R, Tchou P, Xu M, Culver DA. Metabolism-perfusion imaging to predict disease activity in cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011;28:50-5.PubMedGoogle Scholar
  28. 28.
    Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, et al. Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing. Chest 2008;133:1426-35.PubMedCrossRefGoogle Scholar
  29. 29.
    Tadamura E, Yamamuro M, Kubo S, Kanao S, Hosokawa R, Kimura T, et al. Images in cardiovascular medicine. Multimodality imaging of cardiac sarcoidosis before and after steroid therapy. Circulation 2006;113:e771-3.PubMedCrossRefGoogle Scholar
  30. 30.
    Takeda N, Yokoyama I, Hiroi Y, Sakata M, Harada T, Nakamura F, et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation 2002;105:1144-5.PubMedCrossRefGoogle Scholar
  31. 31.
    Berrington de Gonzalez A, Mahesh M, Kim KP, Bhargavan M, Lewis R, Mettler F, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009;169:2071-7.PubMedCrossRefGoogle Scholar
  32. 32.
    Fields CL, Ossorio MA, Roy TM, Denny DM, Varga DW. Thallium-201 scintigraphy in the diagnosis and management of myocardial sarcoidosis. South Med J 1990;83:339-42.PubMedCrossRefGoogle Scholar
  33. 33.
    Tellier P, Paycha F, Antony I, Nitenberg A, Valeyre D, Foult JM, et al. Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis. Am J Med 1988;85:189-93.PubMedCrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2012

Authors and Affiliations

  • Michael Soussan
    • 1
    • 2
    Email author
  • Pierre-Yves Brillet
    • 1
    • 3
  • Hilario Nunes
    • 1
    • 4
  • Gabriel Pop
    • 2
  • Matthieu-John Ouvrier
    • 1
    • 2
  • Nicolas Naggara
    • 1
    • 3
  • Dominique Valeyre
    • 1
    • 4
  • Pierre Weinmann
    • 1
    • 2
  1. 1.University Paris 13, Sorbonne Paris CitéBobignyFrance
  2. 2.Department of Nuclear MedicineAP-HP, Avicenne Universitary HospitalBobignyFrance
  3. 3.Department of RadiologyAP-HP, Avicenne Universitary HospitalBobignyFrance
  4. 4.Department of PneumologyAP-HP, Avicenne Universitary HospitalBobignyFrance

Personalised recommendations